Bisantrene is an anthracenyl bishydrazone with anthracycline-like antineoplastic activity and an antimetabolite.[1] Bisantrene intercalates with and disrupts the configuration of DNA, resulting in DNA single-strand breaks, DNA-protein crosslinking, and inhibition of DNA replication. This agent is similar to doxorubicin in chemotherapeutic activity, but unlike anthracyclines like doxorubicin, it exhibits little cardiotoxicity.[2]
In addition to its anthracycline-like activity, a July 2020 seminal article by Su, R et al. at the City of Hope Hospital in Los Angeles, California, USA first identified bisantrene to also be a potent (IC50 = 142nM) inhibitor of the Fat Mass and Obesity (FTO) associated protein, which is a m6A RNA demethylase. The same study found that bisantrene is a weak inhibitor of ALKBH5, which is the only other demethylase, i.e. bisantrene is also a selective inhibitor of FTO.[3]
In 2021, bisantrene was demonstrated preclinically to be cardioprotective when administered together with cardiotoxic anthracyclines.[4]
A bisantrene combination treatment is currently (as at early 2024) nearing the end of a Phase II clinical trial to assess its efficacy in treating AML in heavily pretreated patients and to assess any adverse side effects, including any cardiotoxicity of the combination. The December 2023 interim findings are given in the History section.[5]
Unlike other anthracycline chemotherapeutics, Bisantrene shows low levels of cardiotoxicity. In a Phase III metastatic breast cancer clinical, patients were exposed to cumulative doses in excess of 5440mg/m2 without developing cardiac damage.[medical citation needed][6] The same study observed significantly lower rates of hair loss and nausea compared to patients given doxorubicin.[8]
Three Mechanisms of Action
Bisantrene has three distinct mechanisms of action.
Bisantrene contains an appropriately sized planar electron-rich chromophore to be a DNA intercalating agent, and in vitro, it is a potent inhibitor of DNA and RNA synthesis.[6][7]
Bisantrene is also a potent and selective inhibitor of the FTO enzyme, which is an m6A mRNA demethylase. Bisantrene acts by occupying FTO's catalytic pocket. This is a relatively recent discovery (July 2020).[3]
Finally, the University of Newcastle and the Hunter Medical Research Institute found in late 2021 preclinical research that bisantrene has a cardioprotective mechanism of action when administered together with a cardiotoxic drug such as doxorubicin. As at early 2024, the molecular basis for this cardioprotective effect hasn't been announced by the researchers.[4]
Bisantrene's cardioprotective mechanism of action is important because "15 of the 35 commercially available anti-cancer drugs have direct cardiotoxic effects on HCM (human cardiomyocytes)."[9]
According to the Australian Cardiovascular Alliance Cardio-Oncology Working Group , a drug which is simultaneously anticancer and cardioprotective is the "Holy Grail" of Cardio-Oncology.[10]
History
Bisantrene was developed by Lederle Laboratories during the 1970s, a subsidiary of American Cyanamid, as a less cardiotoxic alternative to anthracyclines. Across the 1980s and early 1990s, over 40 clinical trials were conducted using Bisantrene. The National Cancer Institute (NCI)] undertook a large scale trial using Bisantrene under the name "Orange Crush", including a range of preclinical trials which found bisantrene to be inactive when taken orally, though was found to be efficacy towards some cancer cells intravenous, intraperitoneal, or subcutaneous.[medical citation needed]
In the 1980s, forty-four patients with metastatic breast cancer who had undergone extensive combination chemotherapy with doxorubicin and had failed to respond to the combination, were treated with bisantrene. From 40 patients that were evaluated, 9 showed a partial response, and 18 showed the cancer was not progressive but stabilised.[11]
Bisantrene was approved for human medical use in France in 1990 to target Acute Myeloid Leukemia (AML) cancers.[citation needed]
It has undergone 46 Phase II trials with 1,800 patients to test its efficacy against fighting cancer cells.[citation needed]
The drug was delisted in the early 1990s due to a series of pharmaceutical mergers and acquisitions.[citation needed]
In November 2019, researchers at the City of Hope Hospital in Los Angeles, California published that a drug with codename "CS1" is a potent and specific inihibitor of FTO, a m6A mRNA demethylase. This article didn't identify that "CS1" is actually bisantrene.[12]
In 2020 at Sheba Hospital, Tel Aviv, Israel, four out of 10 heavily pretreated AML patients responded to bisantrene administered as a single agent. All four of these responding patients had extramedullary disease.[13]
In July 2020, researchers at the City of Hope Hospital in Los Angeles, California published that bisantrene (for which they mostly used the codename "CS1") is a potent and specific inihibitor of FTO, a m6A mRNA demethylase. The fact that "CS1" is actually bisantrene is mentioned near the start of the Discussion section of the article.[3]
In 2021, researchers at the University of Chicago used bisantrene (which they referred to as "CS1", using the codename adopted by the City of Hope Hospital) to successfully inhibit FTO in a preclinical experiment.[14]
In a preclinical trial published in January 2022, researchers at the University of Lille used bisantrene to inhibit FTO in order to test whether an FTO inhibitor could potentially be used to treat disregulation of glucose metabolism in Type 2 diabetes.[15]
In 2022 researchers at the University of Texas tested a bisantrene, venetoclax and decitabine combination for AML preclinically.[16]
Based on the 2020 clinical study at Sheba Hospital and the two University of Texas pre-clinicals cited above, the most recent clinical trial is the one currently (as at early 2024) underway as a combination treatment for AML in heavily pretreated patients at Sheba Hospital, Tel Aviv, Israel. In the dose-finding stage, three out of six of the heavily pretreated patients were bridged to a bone marrow transplant.[17] Interim results of the expansion stage were announced in December 2023 in a poster presented at the 2023 American Society of Haematologists conference. The results are promising for such heavily pre-treated patients. Six patients recovered sufficiently to be bridged to a bone marrow transplant. No cardiotoxity of the Bisantrene, Fludarabine and Clofarabin combination was observed.[5]
In November 2023, researchers at the University of Newcastle and at Race Oncology Limited jointly published a preclinical study in the peer-reviewed journal Blood. It found that bisanantrene is synergistic with the hypomethalating agent decitabine for treatment of AML. The researchers recommended that this combination should proceed to the clinic.[18]
Alternate Names for Bisantrene
Names
Bisantrene's chemical name is 9, 10-antrhracenedicarboxaldehydebis [(4, 5-dihydro-1H-imidazole-2-yl) hydrazine] dihydrochloride.
Bisantrene was given the nickname “Orange Crush” in the 1980s due to its fluorescent orange color when in solution.[19]
Bisantrene is also sometimes referred to as "CS1" in cancer research journals, starting with the July 2020 seminal article by Su, R et al. The fact that "CS1" is actually bisantrene is mentioned near the start of the Discussion section of that article.[3]
Related Research Articles
Daunorubicin, also known as daunomycin, is a chemotherapy medication used to treat cancer. Specifically it is used for acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), and Kaposi's sarcoma. It is administered by injection into a vein. A liposomal formulation known as liposomal daunorubicin also exists.
Anthracyclines are a class of drugs used in cancer chemotherapy that are extracted from Streptomyces bacterium. These compounds are used to treat many cancers, including leukemias, lymphomas, breast, stomach, uterine, ovarian, bladder cancer, and lung cancers. The first anthracycline discovered was daunorubicin, which is produced naturally by Streptomyces peucetius, a species of Actinomycetota. Clinically the most important anthracyclines are doxorubicin, daunorubicin, epirubicin and idarubicin.
Azacitidine, sold under the brand name Vidaza among others, is a medication used for the treatment of myelodysplastic syndrome, myeloid leukemia, and juvenile myelomonocytic leukemia. It is a chemical analog of cytidine, a nucleoside in DNA and RNA. Azacitidine and its deoxy derivative, decitabine were first synthesized in Czechoslovakia as potential chemotherapeutic agents for cancer.
Epirubicin is an anthracycline drug used for chemotherapy. It can be used in combination with other medications to treat breast cancer in patients who have had surgery to remove the tumor. It is marketed by Pfizer under the trade name Ellence in the US and Pharmorubicin or Epirubicin Ebewe elsewhere.
Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal cells that build up in the bone marrow and blood and interfere with normal blood cell production. Symptoms may include feeling tired, shortness of breath, easy bruising and bleeding, and increased risk of infection. Occasionally, spread may occur to the brain, skin, or gums. As an acute leukemia, AML progresses rapidly, and is typically fatal within weeks or months if left untreated.
Dexrazoxane hydrochloride is a cardioprotective agent. It was discovered by Eugene Herman in 1972. The IV administration of dexrazoxane is in acidic condition with HCl adjusting the pH.
Decitabine, sold under the brand name Dacogen among others, acts as a nucleic acid synthesis inhibitor. It is a medication for the treatment of myelodysplastic syndromes, a class of conditions where certain blood cells are dysfunctional, and for acute myeloid leukemia (AML). Chemically, it is a cytidine analog.
Acute myeloblastic leukemia with maturation (M2) is a subtype of acute myeloid leukemia (AML).
Cluster of differentiation antigen 135 (CD135) also known as fms like tyrosine kinase 3, receptor-type tyrosine-protein kinase FLT3, or fetal liver kinase-2 (Flk2) is a protein that in humans is encoded by the FLT3 gene. FLT3 is a cytokine receptor which belongs to the receptor tyrosine kinase class III. CD135 is the receptor for the cytokine Flt3 ligand (FLT3L).
Pixantrone is an experimental antineoplastic (anti-cancer) drug, an analogue of mitoxantrone with fewer toxic effects on cardiac tissue. It acts as a topoisomerase II poison and intercalating agent. The code name BBR 2778 refers to pixantrone dimaleate, the actual substance commonly used in clinical trials.
Sapacitabine is a chemotherapeutic drug developed by US biotechnology firm Cyclacel currently undergoing clinical trials against leukemia.
Omacetaxine mepesuccinate is a pharmaceutical drug substance that is indicated for treatment of chronic myeloid leukemia (CML).
Crenolanib besylate is an investigational inhibitor being developed by AROG Pharmaceuticals, LLC. The compound is currently being evaluated for safety and efficacy in clinical trials for various types of cancer, including acute myeloid leukemia (AML), gastrointestinal stromal tumor (GIST), and glioma. Crenolanib is an orally bioavailable benzimidazole that selectively and potently inhibits signaling of wild-type and mutant isoforms of class III receptor tyrosine kinases (RTK) FLT3, PDGFR α, and PDGFR β. Unlike most RTK inhibitors, crenolanib is a type I mutant-specific inhibitor that preferentially binds to phosphorylated active kinases with the ‘DFG in’ conformation motif.
Quizartinib, sold under the brand name Vanflyta, is an anti-cancer medication used for the treatment of acute myeloid leukemia.
Midostaurin, sold under the brand name Rydapt by Novartis, is a multi-targeted protein kinase inhibitor that has been investigated for the treatment of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and advanced systemic mastocytosis. It is a semi-synthetic derivative of staurosporine, an alkaloid from the bacterium Streptomyces staurosporeus.
Volasertib is an experimental small molecule inhibitor of the PLK1 protein being developed by Boehringer Ingelheim for use as an anti-cancer agent. Volasertib is the second in a novel class of drugs called dihydropteridinone derivatives.
Vadastuximab talirine is an antibody-drug conjugate (ADC) directed to CD33 (siglec-3) which is a transmembrane receptor expressed on cells of myeloid lineage. The experimental drug, being developed by Seattle Genetics, was in clinical trials for the treatment of acute myeloid leukemia (AML).
Filanesib is a kinesin spindle protein (KIF11) inhibitor which has recently been proposed as a cancer treatment, specifically for multiple myeloma.
Venetoclax, sold under the brand names Venclexta and Venclyxto, is a medication used to treat adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or acute myeloid leukemia (AML).
Gilteritinib, sold under the brand name Xospata, is an anti-cancer drug. It acts as an inhibitor of FLT3, hence it is a tyrosine kinase inhibitor.
1 2 3 Spiegel (January 1982). "Phase I Clinical Trial of 9,10-Anthracene Dicarboxaldehyde (Bisantrene) Administered in a Five-Day Schedule". Cancer Research. 42 (1): 354–358. PMID7053862.
↑ Cowan JD, Neidhart J, McClure S, Coltman CA, Gumbart C, Martino S, etal. (August 1991). "Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study". Journal of the National Cancer Institute. 83 (15): 1077–1084. doi:10.1093/jnci/83.15.1077. PMID1875415.
↑ Su, Rui (13 November 2019). "Effective Novel Fto Inhibitors Show Potent Anti-Cancer Efficacy and Suppress Drug Resistance". Blood. 134 (134, Supplement 1): 233. doi:10.1182/blood-2019-124535.
↑ Verrills, Nicole M (November 2023). "Preclinical Evaluation of Bisantrene As Single Agent and in Combination with Decitabine for Acute Myeloid Leukemia". Blood. 142 (142 (Supplement 1)): 5773. doi:10.1182/blood-2023-188353.
↑ "Bisantrene Hydrochloride (Code C77218)". NCI Thesaurus. National Cancer Institute, U.S. Department of Health and Human Services. 28 June 2021. Archived from the original on 2021-07-12. Retrieved 12 July 2021.
This page is based on this Wikipedia article Text is available under the CC BY-SA 4.0 license; additional terms may apply. Images, videos and audio are available under their respective licenses.
